Annovis Bio Inc
annovisbio.comWhat Do They Do?
Develops drug candidates for people with Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions.
10-K for FY2025, filed Mar 13, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 13, 2026
Who Are Their Customers?
If buntanetap is approved, Annovis plans to work with pharmaceutical companies to sell through neurologists, geriatric specialists and primary care physicians, potentially using collaboration, co-promotion or distribution arrangements.
10-K for FY2025, filed Mar 13, 2026If buntanetap is approved for AD or PD, we plan to enter into sales and marketing agreements with one or several pharmaceutical companies…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$14.8MView ↗
- ▲ +138% (Loss)
- vs −$6.2M in Q2 FY2025
-
Mar 25, 2026
Chief financial officer Mark Guerin departed
The company anticipated appointing CEO Maria Maccecchini as acting CFO until a replacement was identified.
Sources
8-K, filed Mar 25, 2026
Effective March 23, 2026, Mark Guerin is no longer employed as as Chief Financial Officer of Annovis Bio, Inc. (the “Company”). Mr.…View ↗
Broader buntanetap program
The earlier pipeline described buntanetap for chronic neurodegeneration including Alzheimer’s and Parkinson’s; the latest also includes Parkinson’s disease dementia and combination therapies.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 13, 2026Our pipeline consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301…View ↗
Our pipeline consists of: buntanetap for chronic neurodegeneration - including AD, PD and PDD - as well as within certain combination…View ↗
Loading...
